Printer Friendly

MARION MERRELL DOW PROPOSES THREE NEW MEMBERS TO JOIN ITS BOARD OF DIRECTORS

 MARION MERRELL DOW PROPOSES THREE NEW MEMBERS
 TO JOIN ITS BOARD OF DIRECTORS
 KANSAS CITY, Mo., Feb. 20 /PRNewswire/ -- Marion Merrell Dow Inc. (NYSE: MKC) today announced the nomination of three new members for its board of directors. The nominations were approved by the board of directors at its meeting today and will be submitted to shareholders for a vote at the annual meeting in May.
 The three nominees:
 William S. Stavropoulos, Ph.D., senior vice president of The Dow Chemical Co. and president of Dow U.S.A. Stavropoulos has been with Dow Chemical for 25 years.
 Paul G. Rogers, a partner in the law firm of Hogan & Hartson, Washington, D.C. Rogers served in the U.S. House of Representatives for 24 years and was active in enacting major health care legislation. Rogers served as special counsel to the board of Marion Laboratories Inc., a predecessor company to Marion Merrell Dow, from 1979 to 1989.
 R. Malcolm Barbour, senior vice president, Strategic Development, for Marion Merrell Dow. Before Marion Merrell Dow's formation in 1989, Barbour had been executive vice president of Merrell Dow Pharmaceuticals Inc. He had been associated with The Dow Chemical Co. in various capacities since 1962.
 Barbour's nomination represents the start of an effort to broaden participation of the company's executives with the board of directors. Through a rotation system, the board will nominate one senior management associate each year to a one-year term as a director. After that year, the executive will serve as an advisory director for one additional year and another executive will be nominated to become a director. Under the plan, at any given time the board will have one senior management associate as a member and one as an advisory director. If elected by the shareholders, Barbour will be the first such director. Walter M. Lovenberg, Ph.D., executive vice president of Marion Merrell Dow and president of the Marion Merrell Dow Research Institute, will rotate to an advisory director status for the next year.
 Headquartered in Kansas City, Marion Merrell Dow is a global pharmaceutical company that focuses on the discovery, development, manufacture and sale of prescription and over-the-counter pharmaceutical products. The company markets more than 140 products, principally in North America, Europe and the Pacific Basin.
 -0- 2/20/92
 /CONTACT: Larry W. Wheeler or David M. Thompson both of Marion Merrell Dow, 816-966-4000/
 (MKC) CO: Marion Merrell Dow Inc. ST: Missouri IN: MTC SU: PER


BB -- DV007 -- 1071 02/20/92 15:43 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 20, 1992
Words:417
Previous Article:J. DENNIS O'CONNOR, SETH E. SCHOFIELD ELECTED DIRECTORS OF PITTSBURGH NATIONAL BANK
Next Article:HARSCO CORPORATION ANNOUNCES FOURTH QUARTER AND YEAR-END RESULTS FOR 1991
Topics:


Related Articles
MARION MERRELL DOW NAMES NEW HEAD OF RESEARCH AND DEVELOPMENT
SHAREHOLDERS OF MARION MERRELL DOW ELECT DIRECTORS, HEAR PERFORMANCE UPDATE
MARION MERRELL DOW BOARD OF DIRECTORS NOMINATES JUDITH A. HEMBERGER, PH.D., TO BOARD
MARION MERRELL DOW SIMPLIFIES GLOBAL BUSINESS STRUCTURE, NAMES LEADERS
MARION MERRELL DOW ANNOUNCES PLANS FOR TRANSITION IN SENIOR MANAGEMENT
MARION MERRELL DOW INC. BOARD OF DIRECTORS NOMINATES PETER W. LADELL TO BOARD
KEITH R. MCKENNON NAMED TO BOARD OF DIRECTORS OF MARION MERRELL DOW INC.
JUDITH A. HEMBERGER, PH.D., TO LEAD DRUG REGULATORY AFFAIRS FOR HOECHST MARION ROUSSEL
PETER W. LADELL TO LEAD NORTH AMERICAN UNIT OF HOECHST MARION ROUSSEL
FRANK L. DOUGLAS, PH.D., M.D., TO LEAD RESEARCH FOR HOECHST MARION ROUSSEL

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters